Stock ATHXQ ATHERSYS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Athersys, Inc.

Equities

ATHXQ

US04744L2051

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 12:43:32 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.00462 USD +0.43% Intraday chart for Athersys, Inc. +15.00% -77.00%
Apr. 11 North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge DJ
Apr. 05 Athersys, Inc. Announces Board Changes CI

Business Summary

Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).

Number of employees: 24

Sales per Business

USD in Million2021Weight2022Weight Delta
Regenerative Medicine
100.0 %
6 100.0 % 5 100.0 % -3.43%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
6 100.0 % 5 100.0 % -3.43%

Managers

Managers TitleAgeSince
Rakesh Ramachandran CTO
 Chief Tech/Sci/R&D Officer - 96-12-31
Kasey Rosado BRD
 Director/Board Member 50 22-07-31
Ellen Gurley IRC
 Investor Relations Contact - 23-01-31
Manal Morsy LAW
 General Counsel - 12-12-31

Members of the board

Members of the board TitleAgeSince
Kasey Rosado BRD
 Director/Board Member 50 22-07-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,718,765 61,243,341 ( 99.23 %) 0 99.23 %

Shareholders

NameEquities%Valuation
HEALIOS K.K.
1.057 %
652,421 1.057 % 3 915 $
Daniel Camardo
0.4623 %
285,341 0.4623 % 1 712 $
Strategic Wealth Designers LLC
0.4451 %
274,738 0.4451 % 1 648 $
Maia Hansen
0.1134 %
70,010 0.1134 % 420 $
Ismail Kola
0.0976 %
60,226 0.0976 % 361 $
Jack Wyszomierski
0.0569 %
35,141 0.0569 % 211 $
Jane Wasman
0.0569 %
35,141 0.0569 % 211 $
John Harrington
0.0440 %
27,169 0.0440 % 163 $
Joseph Nolan
0.0356 %
21,951 0.0356 % 132 $
William Lehmann
0.0302 %
18,661 0.0302 % 112 $

Company contact information

Athersys, Inc.

3201 Carnegie Avenue

44115-2634, Cleveland

+216 431 9900

http://www.athersys.com
address Athersys, Inc.(ATHXQ)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ATHERSYS, INC. Stock Athersys, Inc.
-77.00% 284K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.87% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.50% 97.5B
ARGENX SE Stock argenx SE
+1.86% 22.19B
BIONTECH SE Stock BioNTech SE
-16.56% 21.33B
GENMAB A/S Stock Genmab A/S
-8.49% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-21.09% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.24% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.89% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATHXQ Stock
  4. Company Athersys, Inc.